ES2600879T3 - Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas - Google Patents
Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas Download PDFInfo
- Publication number
- ES2600879T3 ES2600879T3 ES10830777.8T ES10830777T ES2600879T3 ES 2600879 T3 ES2600879 T3 ES 2600879T3 ES 10830777 T ES10830777 T ES 10830777T ES 2600879 T3 ES2600879 T3 ES 2600879T3
- Authority
- ES
- Spain
- Prior art keywords
- fvw
- amino acid
- acid sequence
- kits
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Polipéptido que comprende una primera secuencia de aminoácidos presente en un polipéptido de FvW y una segunda secuencia de aminoácidos heteróloga con respecto a la primera, en el que dicho polipéptido es capaz de unirse a un FVIII y formar dímeros, oligómeros y multímeros, con la condición de que el polipéptido carezca, como mínimo, de los dominios D4, B1, B2, B3, C1, C2 y CK del FvW, en el que la segunda secuencia de aminoácidos corresponde a una inmunoglobulion Fc, en el que la segunda secuencia de aminoácidos es un extremo carboxiterminal con respecto a la primera secuencia de aminoácidos, y en el que la primera secuencia de aminoácidos es tal como se indica en SEC ID NO:11, SEC ID NO:13 o SEC ID NO:15.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US261145P | 2001-01-12 | ||
US26114509P | 2009-11-13 | 2009-11-13 | |
PCT/US2010/056496 WO2011060242A2 (en) | 2009-11-13 | 2010-11-12 | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2600879T3 true ES2600879T3 (es) | 2017-02-13 |
Family
ID=43992414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10830777.8T Active ES2600879T3 (es) | 2009-11-13 | 2010-11-12 | Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas |
Country Status (20)
Country | Link |
---|---|
US (1) | US8759293B2 (es) |
EP (1) | EP2499165B1 (es) |
JP (1) | JP5876416B2 (es) |
KR (1) | KR101808751B1 (es) |
CN (1) | CN102648212B (es) |
AU (1) | AU2010319425B2 (es) |
BR (1) | BR112012011740A2 (es) |
CA (1) | CA2780542C (es) |
CL (1) | CL2012001258A1 (es) |
ES (1) | ES2600879T3 (es) |
HK (1) | HK1170244A1 (es) |
HU (1) | HUE029454T2 (es) |
IL (1) | IL219679A (es) |
MX (1) | MX2012005527A (es) |
NZ (1) | NZ600278A (es) |
PL (1) | PL2499165T3 (es) |
PT (1) | PT2499165T (es) |
RU (1) | RU2579977C2 (es) |
WO (1) | WO2011060242A2 (es) |
ZA (1) | ZA201203795B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプramのチエツク方法 |
RU2549676C2 (ru) | 2007-06-01 | 2015-04-27 | Юниверсити Оф Мэрилэнд, Балтимор | СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
BR112012011740A2 (pt) | 2009-11-13 | 2018-03-27 | Grifols Therapeutics Inc | polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii |
CN103154036B (zh) | 2010-07-28 | 2016-05-11 | 格利克尼克股份有限公司 | 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物 |
WO2013098676A1 (en) | 2011-12-30 | 2013-07-04 | Grifols, S.A. | Method for purifying factor viii |
SG11201403764XA (en) * | 2012-01-12 | 2014-07-30 | Biogen Idec Inc | Chimeric factor viii polypeptides and uses thereof |
PT2802668T (pt) | 2012-01-12 | 2018-12-04 | Puget Sound Blood Center | Processos para reduzir a imunogenicidade contra o fator viii em indivíduos a receber terapêutica com fator viii |
EP2814840B1 (en) | 2012-02-15 | 2019-11-13 | Bioverativ Therapeutics Inc. | Factor viii compositions and methods of making and using same |
EP3549953A1 (en) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
CN104411716B (zh) | 2012-04-24 | 2018-09-07 | 诺和诺德股份有限公司 | 适用于治疗血友病的化合物 |
EP3674410A1 (en) * | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
CN104718223A (zh) | 2012-08-20 | 2015-06-17 | 格利克尼克股份有限公司 | 具有抗原结合和多价FCγ受体结合活性的分子 |
EP2912186B1 (en) | 2012-10-24 | 2021-01-06 | Platelet Targeted Therapeutics LLC | Platelet targeted treatment |
GB201304973D0 (en) * | 2013-03-19 | 2013-05-01 | Profactor Pharma Ltd | Recombinant protein |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
WO2014198699A2 (en) * | 2013-06-12 | 2014-12-18 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
SG11201509313PA (en) * | 2013-06-28 | 2016-01-28 | Biogen Ma Inc | Thrombin cleavable linker with xten and its uses thereof |
EP3013359A4 (en) * | 2013-06-28 | 2017-01-25 | Biogen MA Inc. | Thrombin cleavable linker |
US10947269B2 (en) | 2013-08-08 | 2021-03-16 | Bioverativ Therapeutics Inc. | Purification of chimeric FVIII molecules |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
KR102409250B1 (ko) * | 2014-01-10 | 2022-06-14 | 바이오버라티브 테라퓨틱스 인크. | 인자 viii 키메라 단백질 및 이들의 용도 |
US10626164B2 (en) * | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
US9701933B2 (en) * | 2014-09-19 | 2017-07-11 | Sarfaraz K. Niazi | Harvesting and purification or perfusion yielder (HAPPY) device |
EP3265483B1 (en) * | 2015-03-06 | 2019-12-11 | CSL Behring Lengnau AG | Modified von willebrand factor having improved half-life |
KR20180006453A (ko) | 2015-05-22 | 2018-01-17 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 |
DK3298036T3 (da) | 2015-05-22 | 2022-06-07 | CSL Behring Lengnau AG | Fremgangsmåder til forberedelse af modificeret von Willebrand faktor |
WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
WO2017117630A1 (en) * | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated von willebrand factor |
WO2017214321A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
JP6877469B2 (ja) | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチMogam Institute For Biomedical Research | Fviiiおよびvwf因子を含むキメラタンパク質、ならびにそれらの使用 |
JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
DK3538133T3 (da) * | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
MX2019006573A (es) | 2016-12-09 | 2019-11-18 | Gliknik Inc | Optimizacion de fabricacion de gl-2045 un stradomer multimerizante. |
AU2018256453B2 (en) | 2017-04-20 | 2024-02-08 | The University Of Chicago | Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies |
GB201707139D0 (en) * | 2017-05-04 | 2017-06-21 | Imp Innovations Ltd | Polypeptides |
BR112019026743A2 (pt) | 2017-06-22 | 2020-06-30 | CSL Behring Lengnau AG | modulação da imunogenicidade de fviii através de vwf truncado |
WO2019010496A1 (en) * | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | TREATMENT OF PATIENTS WITH A SERIOUS FORM OF VON WILLEBRAND'S DISEASE UNRESENGING SURGICAL INTERVENTION BY RECOMBINANT VWF ADMINISTRATION |
WO2019084691A1 (en) * | 2017-11-01 | 2019-05-09 | Queen's University At Kingston | Von willebrand factor proteins for treating bleeding disorders |
TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療a型血友病的方法 |
US10654911B1 (en) | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
US20220389082A1 (en) | 2019-07-04 | 2022-12-08 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
WO2024106355A1 (ja) * | 2022-11-14 | 2024-05-23 | セルジェンテック株式会社 | 血液凝固第viii因子改変体を産生するエクスビボ遺伝子治療用細胞 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234991A (en) | 1975-07-29 | 1993-08-10 | Pasteur Merieux Serums And Vaccines | Porous mineral support coated with an aminated polysaccharide polymer |
US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
US5149637A (en) | 1987-04-06 | 1992-09-22 | Scripps Clinic & Research Foundation | Recombinant Factor VIIIC fragments |
US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
FR2616437B1 (fr) | 1987-06-11 | 1990-09-07 | Ibf | Polymeres composites, leur preparation et leur utilisation en chromatographie liquide |
US5200510A (en) * | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
US5683912A (en) | 1994-07-21 | 1997-11-04 | The Salk Institute For Biological Studies | Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit |
FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
FR2657884B1 (fr) | 1990-02-05 | 1994-09-02 | Tm Innovation | Procede pour la preparation du facteur viii humain et d'analogues du facteur viii. |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
ES2233924T3 (es) * | 1991-06-20 | 2005-06-16 | Aventis Behring L.L.C. | Un procedimiento para preparar fragmentos terapeuticos de factor von willebrand. |
DE4204694C3 (de) * | 1992-02-01 | 1995-10-12 | Octapharma Ag | Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US5268097A (en) | 1992-06-19 | 1993-12-07 | Sepracor Inc. | Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same |
CA2148484A1 (en) | 1992-11-13 | 1994-05-26 | Stewart Lyman | Novel cytokine designated elk ligand |
DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
US5849989A (en) | 1994-10-07 | 1998-12-15 | Ontogeny, Inc. | Insulin promoter factor, and uses related thereto |
US5688912A (en) | 1995-09-22 | 1997-11-18 | Bayer Corporation | Peptide ligands which bind to von willebrand factor |
ATE425175T1 (de) | 1996-01-23 | 2009-03-15 | Operon Biotechnologies Inc | Verfahren und zusammensetzungen zur bestimmung von sequenzen von nukleinsäure-molekülen |
US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
AT403765B (de) | 1996-04-12 | 1998-05-25 | Immuno Ag | Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex |
US6074832A (en) | 1996-07-19 | 2000-06-13 | The Regents Of The University Of Michigan | DNA encoding canine von Willebrand factor and methods of use |
AU3671197A (en) | 1996-07-19 | 1998-02-10 | Regents Of The University Of Michigan, The | Dna encoding canine von willebrand factor and methods of use |
US6063593A (en) | 1996-11-12 | 2000-05-16 | University Of Southern California University Park Campus | TGFβ1 responsive bone marrow derived cells to express a recombinant protein |
ATE371673T1 (de) | 1996-11-27 | 2007-09-15 | Genentech Inc | Affinitätsreinigung von polypeptiden an einer protein a-matrix |
AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
AT406867B (de) | 1997-02-27 | 2000-10-25 | Immuno Ag | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
US6489290B2 (en) | 1997-03-27 | 2002-12-03 | Trustees Of Boston University | Antiplatelet agent |
US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
NZ501774A (en) | 1997-07-22 | 2002-02-01 | Qiagen Genomics Inc | Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000028021A1 (de) | 1998-11-10 | 2000-05-18 | Baxter Aktiengesellschaft | Ein faktor viii-polypeptid mit faktor viii:c-aktivität |
US7144996B1 (en) | 1999-03-05 | 2006-12-05 | Genentech, Inc. | Nucleic acid encoding human suppressor of fused |
US20050164386A1 (en) | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US20060099685A1 (en) | 1999-04-15 | 2006-05-11 | Yallop Christopher A | Recombinant expression of factor VIII in human cells |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
CA2390691C (en) | 1999-12-24 | 2016-05-10 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US6664112B2 (en) | 2000-06-02 | 2003-12-16 | Blue Heron Biotechnology, Inc. | Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
WO2002010437A2 (en) | 2000-07-28 | 2002-02-07 | Blood Center Research Foundation | Synthetic and recombinant substrates for the detection of the von willebrand factor-cleaving protease |
AUPR278301A0 (en) | 2001-01-31 | 2001-02-22 | Bionomics Limited | A novel gene |
JP2003284570A (ja) * | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子(vWF)切断酵素 |
ATE513038T1 (de) | 2001-09-18 | 2011-07-15 | Synageva Biopharma Corp | Produktion eines transgenen vogels mittels cytoplasmainjektion |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
AU2002364509A1 (en) | 2001-11-30 | 2003-06-17 | Emory University | Factor viii c2 domain variants |
WO2003054232A2 (en) | 2001-12-13 | 2003-07-03 | Blue Heron Biotechnology, Inc. | Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
ES2285188T3 (es) | 2002-07-15 | 2007-11-16 | Immunex Corporation | Metodo y medios para controlar sialilacion de proteinas producidas por celulas de mamifero. |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP2077121B1 (en) * | 2003-05-06 | 2011-02-09 | Syntonix Pharmaceuticals, Inc. | Clotting factor VII-Fc chimeric proteins for treatment of a hemostatic disorder |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
JP2005073528A (ja) * | 2003-08-28 | 2005-03-24 | Genetics Inst Llc | 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物 |
EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
EP3184551A1 (en) | 2004-08-12 | 2017-06-28 | Lipoxen Technologies Limited | Sialic acid derivatives |
CA2578046A1 (en) | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
GB0423974D0 (en) * | 2004-10-28 | 2004-12-01 | Ares Trading Sa | Proteins |
PT1835938E (pt) | 2004-12-27 | 2013-11-06 | Baxter Int | Conjugados de polímero-factor de von willebrand |
DE602006015281D1 (de) | 2005-01-14 | 2010-08-19 | Ablynx Nv | Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind |
EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US20080206246A1 (en) | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
WO2007102946A2 (en) * | 2006-01-23 | 2007-09-13 | Amgen Inc. | Crystalline polypeptides |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
KR20090031897A (ko) | 2006-06-12 | 2009-03-30 | 리셉터 바이오로직스 인크 | 전-세포 표면 수용체-특이적 치료제 |
CN101557830B (zh) | 2006-12-15 | 2016-06-08 | 巴克斯特国际公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
WO2008077616A1 (en) * | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
AU2008345558B2 (en) | 2007-12-27 | 2014-08-21 | Baxalta GmbH | Methods for differentiating plasma-derived protein from recombinant protein in a sample |
AR069989A1 (es) | 2007-12-28 | 2010-03-03 | Baxter Int | Formulaciones de vwf recombinantes |
US8575104B2 (en) * | 2008-06-24 | 2013-11-05 | Csl Behring Gmbh | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life |
US9120873B2 (en) | 2008-08-21 | 2015-09-01 | Octapharma Ag | Recombinantly produced human factor VIII and IX |
US20110086362A1 (en) | 2009-10-09 | 2011-04-14 | Massachusetts Institute Of Technology | High-Throughput Method for Quantifying Sialylation of Glycoproteins |
BR112012011740A2 (pt) | 2009-11-13 | 2018-03-27 | Grifols Therapeutics Inc | polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii |
-
2010
- 2010-11-12 BR BR112012011740A patent/BR112012011740A2/pt not_active Application Discontinuation
- 2010-11-12 JP JP2012539007A patent/JP5876416B2/ja active Active
- 2010-11-12 EP EP10830777.8A patent/EP2499165B1/en active Active
- 2010-11-12 RU RU2012122402/10A patent/RU2579977C2/ru not_active IP Right Cessation
- 2010-11-12 CN CN201080051549.3A patent/CN102648212B/zh active Active
- 2010-11-12 PT PT108307778T patent/PT2499165T/pt unknown
- 2010-11-12 MX MX2012005527A patent/MX2012005527A/es active IP Right Grant
- 2010-11-12 PL PL10830777T patent/PL2499165T3/pl unknown
- 2010-11-12 AU AU2010319425A patent/AU2010319425B2/en active Active
- 2010-11-12 CA CA2780542A patent/CA2780542C/en active Active
- 2010-11-12 NZ NZ600278A patent/NZ600278A/en not_active IP Right Cessation
- 2010-11-12 WO PCT/US2010/056496 patent/WO2011060242A2/en active Application Filing
- 2010-11-12 US US13/509,309 patent/US8759293B2/en active Active
- 2010-11-12 KR KR1020127013906A patent/KR101808751B1/ko active IP Right Grant
- 2010-11-12 HU HUE10830777A patent/HUE029454T2/en unknown
- 2010-11-12 ES ES10830777.8T patent/ES2600879T3/es active Active
-
2012
- 2012-05-09 IL IL219679A patent/IL219679A/en not_active IP Right Cessation
- 2012-05-14 CL CL2012001258A patent/CL2012001258A1/es unknown
- 2012-05-24 ZA ZA2012/03795A patent/ZA201203795B/en unknown
- 2012-10-29 HK HK12110787.2A patent/HK1170244A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CL2012001258A1 (es) | 2012-09-14 |
IL219679A (en) | 2016-11-30 |
HK1170244A1 (zh) | 2013-02-22 |
US8759293B2 (en) | 2014-06-24 |
KR101808751B1 (ko) | 2017-12-13 |
CN102648212A (zh) | 2012-08-22 |
CA2780542C (en) | 2020-03-24 |
CA2780542A1 (en) | 2011-05-19 |
HUE029454T2 (en) | 2017-03-28 |
IL219679A0 (en) | 2012-07-31 |
PL2499165T3 (pl) | 2017-04-28 |
RU2012122402A (ru) | 2013-12-20 |
EP2499165A4 (en) | 2013-09-11 |
US20120289468A1 (en) | 2012-11-15 |
CN102648212B (zh) | 2014-12-03 |
EP2499165A2 (en) | 2012-09-19 |
AU2010319425B2 (en) | 2015-07-02 |
MX2012005527A (es) | 2012-08-08 |
WO2011060242A3 (en) | 2011-10-13 |
WO2011060242A2 (en) | 2011-05-19 |
NZ600278A (en) | 2014-04-30 |
EP2499165B1 (en) | 2016-09-14 |
ZA201203795B (en) | 2014-10-29 |
JP2013510581A (ja) | 2013-03-28 |
JP5876416B2 (ja) | 2016-03-02 |
PT2499165T (pt) | 2016-10-28 |
KR20120113214A (ko) | 2012-10-12 |
BR112012011740A2 (pt) | 2018-03-27 |
RU2579977C2 (ru) | 2016-04-10 |
AU2010319425A1 (en) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2600879T3 (es) | Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas | |
ES2563091T3 (es) | Polipéptidos modificados genéticamente que tienen duración de acción potenciada | |
CO6210757A2 (es) | Proeina de fusion que comprende prame o un fragmento inmunogenico del mismo | |
ES2602971T3 (es) | Composición de anticuerpo modificado | |
ES2616658T3 (es) | Péptidos que mimetizan el factor de crecimiento y sus usos | |
ES2512141T3 (es) | Análogo peptídico de oxintomodulina | |
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
EA201691669A1 (ru) | Связывающие сывороточный альбумин домены фибронектина iii типа | |
ES2691539T3 (es) | Luciferasas de Oplophorus sintéticas con mayor emisión de luz | |
CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
CO7170123A2 (es) | Complejo del factor viii con xten y proteína del factor von willebrand y sus usos | |
PE20181206A1 (es) | Construcciones especificas del higado, casetes de expresion del factor viii y metodos de uso de estos | |
PE20150650A1 (es) | Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida | |
ES2513716T3 (es) | Enzimas lecitina-colesteros acitransferasa modificadas | |
BR112014019901A2 (pt) | proteínas de fator viii recombinante | |
CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
CR10591A (es) | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol | |
JP2013172734A5 (es) | ||
ES2676499T3 (es) | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones | |
AR092076A1 (es) | Proteinas homodimericas | |
AR089324A1 (es) | Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas | |
AR083454A1 (es) | Antigeno de citomegalovirus | |
EA201401211A1 (ru) | Улучшенные варианты фермента химозина | |
ES2666720T3 (es) | Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano | |
RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E |